Table 1.
The demographic, disease, and treatment characteristics of the study group and sub-groups regarding endoscopic activity.
| Whole Group (n:135) |
Endoscopic Remission (ER) (Mayo 0–1) (n:72) |
Endoscopic Active Disease (Mayo 2–3) (n:63) |
p | ||
|---|---|---|---|---|---|
| Sex—M (%) | 60 | 60 | 58.3 | 0.84 | |
| Age (mean ± SD) | 46.2 ± 13.9 | 46.1 ± 13.1 | 46.6 ± 14.9 | 0.88 | |
| Age at diagnosis (median (IQR)) | 35 (20) | 35 (19) | 35 (22) | 0.98 | |
| Disease duration | 8 (11) | 8 (11) | 7.5 (10) | 0.66 | |
| Disease extent—Montreal (%) | |||||
| E1 | 12 | 13.9 | 8.3 | 0.6 | |
| E2 | 48 | 47.2 | 50 | ||
| E3 | 40 | 38.9 | 41.7 | ||
| Treatment (%) | |||||
| Oral mesalazine | 89.6 | 88.9 | 91.7 | 0.59 | |
| Topical mesalazine | 48.1 | 51.4 | 46.7 | 0.58 | |
| Azathioprine (AZA) | 40 | 41.7 | 40 | 0.84 | |
| Biologic | 30.5 | 31.9 | 30 | 0.81 | |
| Biologic + AZA | 20 | 22.2 | 18.3 | 0.58 | |
| Anti-TNF | 22.2 | 23.6 | 21.7 | 0.79 | |
| Other biologics | 8.3 | 8.3 | 8.3 | 1 | |
| Disease activity (%) | |||||
| Clinical remission | 69 | 87.5 | 51.7 | <0.001 | |
| Mayo 0–1 (ER) | 53.3 | 100 | 0 | - | |
| Mayo 0 | 35.6 | 66.7 | 0 | - | |
| Laboratory (mean ± SD, median (IQR)) | |||||
| Hb g/dL | 13.5 ± 1.7 | 14 ± 1.6 | 12.9 ± 1.8 | <0.001 | |
| WBC/mm3 | 6800 (2500) | 6300 (1700) | 7300 (2770) | 0.08 | |
| SR mm/h | 10 (14) | 9 (13) | 11.5 (16) | 0.09 | |
| CRP mg/L | 2.7 (5.1) | 2.1 (1.8) | 5.4 (9.6) | <0.001 | |
| FCP μg/g | 125 (676) | 51 (88) | 613 (810) | <0.001 | |
M: male; SD: standard deviation; IQR: inter-quartile range; Hb: hemoglobulin; WBC: white blood cell; SR: sedimentation rate; CRP: C-reactive protein; FCP: fecal calprotectin.